Analyst Daniel Giraldo of Bank of America Securities reiterated a Buy rating on 4D Molecular Therapeutics, with a price target of $29.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Daniel Giraldo has given his Buy rating due to a combination of factors, primarily the strong progress of 4D-150 in wet age-related macular degeneration (wAMD) and its potential to address a major unmet need in retinal disease. He emphasizes that phase 3 enrollment for the lead wAMD study has been completed ahead of key pivotal data expected in 2027, reflecting robust physician and patient interest in a gene therapy that could provide multi-year durability and reduce treatment burden.
Giraldo also points to upcoming two-year readouts in both wAMD and diabetic macular edema (DME), which he believes will further validate 4D-150’s long-term efficacy and safety, underpinning his sizable risk-adjusted sales forecasts. In addition, he highlights the emerging opportunity in cystic fibrosis with 4D-710, and argues that the current share price does not fully reflect the combined commercial potential of these programs relative to his $29 price objective.
According to TipRanks, Giraldo is a 4-star analyst with an average return of 54.1% and an 83.33% success rate.
In another report released on May 8, Chardan Capital also reiterated a Buy rating on the stock with a $26.00 price target.